Royalty Report: Drugs, Pharmaceuticals, Biotechnology – Collection: 29202

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29202

License Grant
In January 2007, an amendment to the collaboration Agreement with a Canadian biotechnology company to co-develop DHA products from plants of December 2003 was executed, whereby the Licensee acquired exclusive License rights to the plant-based DHA technology developed by the co-collaborator for a period of at least 16 years. As consideration for this exclusive License, the Licensee made a License payment and will be subject to minimum royalties on gross margin, as defined, on future sales by Martek of such plant-based DHA. During the term of the License, the Company may be required to pay additional royalties on sales of products in the future which utilize certain Licensed technologies.  The collaboration obligations under the Agreement expired in June 2007.
Field of Use
The rights granted apply to the use of plants.

IPSCIO Record ID: 2651

License Grant
We entered into a collaboration agreement with a Canadian biotechnology company to co-develop DHA products, the omega-3 fatty acid called docosahexaenoic acid from plants. This arrangement included the reimbursement of expenses incurred by the co-collaborator as well as the payment by us of potential royalties and additional milestone payment amounts if certain scientific results were achieved in the future. In January 2007, an amendment to this agreement was executed. Pursuant to the amendment, the co-collaborator will continue its research and development until June 2007, with expenses to be reimbursed by us through April 2007. Furthermore, we acquired exclusive license rights to the plant-based DHA technology developed by the co-collaborator for a period of at least 16 years.  The Licensor is undisclosed.

IPSCIO Record ID: 240569

License Grant
The Canadian Licensor hereby grants to Licensee a sole and exclusive license in the Territory to make, have made, use, have used, import, have imported, offer for sale, sell and have sold Licensed Products in the Field, with rights to grant sublicenses that are co-extensive with such license, under any and all Licensor Program Intellectual Property (including Licensor Improvements), and Licensors rights in Joint Program Intellectual Property. Licensee shall have the right to assign or otherwise transfer its rights in the license granted herein (or any part thereof) to its Affiliates. Notwithstanding any such assignment, Licensee shall be responsible for the activities, including all reporting and royalty obligations, of such Affiliates as if they were Licensee.

During the Research Term:
(a) Licensee hereby grants Licensor a fully-paid up, non-exclusive, royalty-free, worldwide license, without the right to grant sublicenses, under MARTEK Background Technology, MARTEK Program Intellectual Property (including MARTEK Improvements), and MARTEK’s interest in Joint Program Intellectual Property, for the sole purpose of conducting the activities required in the performance of its obligations hereunder as part of the R&D Program.

(b) Licensor hereby grants to Licensee a fully-paid up, non-exclusive, royalty-free, worldwide license, without the right to grant sublicenses, under SEMBIOSYS Background Technology, SEMBIOSYS Program Intellectual Property (including SEMBIOSYS Improvements), SEMBIOSYS’ interest in Joint Program Intellectual Property, and any relevant Third Party Licenses, for the sole purpose of conducting the activities required in the performance of its obligations hereunder as part of the R&D Program.

License Property
Licensed Product means any product or any part thereof, that (i) the production, manufacture, use or sale of which would infringe any Valid Claim contained in any patent rights licensed to Licensee by Licensor hereunder, or (ii) which is produced through the direct and material use of Licensor Program Know-How or Joint Program Know-How.

Program Intellectual Property means all Patent Rights and Program Know-How. Licensor Program Intellectual Property shall mean Licensor Patent Rights and Licensor Program Know-How. Licensee Program Intellectual Property shall mean Licensee Patent Rights and Licensee Program Know-How. Joint Program Intellectual Property shall mean Joint Patent Rights and Joint Program Know-How.

Licensor Improvements means (a) Inventions which claim (i) methods of transforming genes or expressing genes in plants or (ii) methods of making or using plant oil bodies, and (b) all Program Know-How other than Inventions that is directly-related to (a) above.

Licensee Improvements means (a) Inventions which claim the identification, composition or use (i) of DHA, EPA and/or ARA (arachidonic acid) synthesis genes or (ii) of supplemental genes used or evaluated in the course of performance of the R&D Program for enhancing DHA, EPA or ARA production in plants, and (b) all Program Know-How other than Inventions that is directly related to (a) above.

R&D Program means the research and development program to be conducted by Licensor and Licensee and which is described in the Workplans.

Field of Use
This collaboration agreement is to co-develop DHA products from plants.

Field means the production, manufacture and marketing of DHA, ARA and EPA produced in transgenic plants.  These fatty acids are docosahexaenoic acid, commonly known as DHA, and arachidonic acid, commonly known as ARA.  DHA and ARA may help develop the eyes and central nervous systems of newborns and promote adult mental and cardiovascular health.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.